Epilepsy (monotherapy)
- PO (Adults and Children ≥10 yr): Immediate-release: 25 mg twice daily initially, gradually ↑ at weekly intervals to 200 mg twice daily over a 6-wk period; Extended-release (Qudexy XR or Trokendi XR): 50 mg once daily initially, gradually ↑ at weekly intervals to 400 mg once daily over a 6-wk period.
- PO (Children 2–<10 yr [6–<10 yr for Trokendi XR] and >38 kg): Immediate-release: 25 mg once daily in the evening initially, gradually ↑ at weekly intervals to 125 mg twice daily over a 5–7-wk period; if needed may continue to titrate dose on a weekly basis up to 200 mg twice daily; Extended-release (Qudexy XR or Trokendi XR): 25 mg once daily for 1 wk, then ↑ to 50 mg once daily for 1 wk, then ↑ by 25–50 mg/day at weekly intervals over a 5–7-wk period to target dose of 250–400 mg once daily.
- PO (Children 2–<10 yr [6–<10 yr for Trokendi XR] and 32–38 kg): Immediate-release: 25 mg once daily in the evening initially, gradually ↑ at weekly intervals to 125 mg twice daily over a 5–7-wk period; if needed, may continue to titrate dose on a weekly basis up to 175 mg twice daily; Extended-release (Qudexy XR or Trokendi XR): 25 mg once daily for 1 wk, then ↑ to 50 mg once daily for 1 wk, then ↑ by 25–50 mg/day at weekly intervals over a 5–7-wk period to target dose of 250–350 mg once daily.
- PO (Children 2–<10 yr [6–<10 yr for Trokendi XR] and 23–31 kg): Immediate-release: 25 mg once daily in the evening initially, gradually ↑ at weekly intervals to 100 mg twice daily over a 5–7-wk period; if needed; may continue to titrate dose on a weekly basis up to 175 mg twice daily; Extended-release (Qudexy XR or Trokendi XR): 25 mg once daily for 1 wk, then ↑ to 50 mg once daily for 1 wk, then ↑ by 25–50 mg/day at weekly intervals over a 5–7-wk period to target dose of 200–350 mg once daily.
- PO (Children 2–<10 yr [6–<10 yr for Trokendi XR] and 12–22 kg): Immediate-release: 25 mg once daily in the evening initially, gradually ↑ at weekly intervals to 100 mg twice daily over a 5–7-wk period; if needed, may continue to titrate dose on a weekly basis up to 150 mg twice daily; Extended-release (Qudexy XR or Trokendi XR): 25 mg once daily for 1 wk, then ↑ to 50 mg once daily for 1 wk, then ↑ by 25–50 mg/day at weekly intervals over a 5–7-wk period to target dose of 200–300 mg once daily.
- PO (Children 2–<10 yr [6–<10 yr for Trokendi XR] and ≤11 kg): Immediate-release: 25 mg once daily in the evening initially, gradually ↑ at weekly intervals to 75 mg twice daily over a 5–7-wk period; if needed, may continue to titrate dose on a weekly basis up to 125 mg twice daily; Extended-release (Qudexy XR or Trokendi XR): 25 mg once daily for 1 wk, then ↑ to 50 mg once daily for 1 wk, then ↑ by 25–50 mg/day at weekly intervals over a 5–7-wk period to target dose of 150–250 mg once daily.
Renal Impairment
- PO (Adults): CCr <70 mL/min: ↓ dose by 50%.
Epilepsy (adjunctive therapy)
- PO (Adults and Children ≥17 yr): Immediate-release: 25–50 mg/day initially, ↑ by 25–50 mg/day at weekly intervals up to 200–400 mg/day in 2 divided doses (200–400 mg/day in 2 divided doses for partial seizures or Lennox-Gastaut syndrome and 400 mg/day in 2 divided doses for primary generalized tonic-clonic seizures); Extended-release (Qudexy XR or Trokendi XR): 25–50 mg once daily initially, ↑ by 25–50 mg/day at weekly intervals up to 200–400 mg once daily (for partial seizures or Lennox-Gastaut syndrome) and 400 mg once daily (for primary generalized tonic-clonic seizures).
- PO (Children 2–16 yr): Immediate-release and extended-release (Qudexy XR): 25 mg once daily at night initially for first wk, ↑ at 1–2 wk intervals by 1–3 mg/kg/day up to 5–9 mg/kg/day in 2 divided doses.
- PO (Children 6–16 yr): Extended-release (Trokendi XR): 25 mg once daily at night initially for first wk, ↑ at 1–2 wk intervals by 1–3 mg/kg/day up to 5–9 mg/kg/day given once daily at night.
Renal Impairment
- PO (Adults): CCr <70 mL/min: ↓ dose by 50%.
Migraine Prevention
- PO (Adults and Children ≥12 yr): Immediate-release: 25 mg at night initially, ↑ by 25 mg/day at weekly intervals up to target dose of 100 mg/day in 2 divided doses; Extended-release (Qudexy XR): 25 mg once daily initially, ↑ by 25 mg/day at weekly intervals up to target dose of 100 mg once daily.
Renal Impairment
- PO (Adults): CCr <70 mL/min: ↓ dose by 50%.
